EULAR disease activity | Adalimumab n (%) | Etarnercept n (%) | Rituximab n (%) |
0 Months n % HDA > 5.1 MDA > 3.2 < 5.1 LDA > 2.6 < 3.2 Remission < 2.6 | 41 34 (82.9) 7 (17.1) | 29 23 (79.3) 6 (20.7) | 50 44 (88) 5 (10) 1 (2) |
6 Months n % HDA > 5.1 MDA > 3.2 < 5.1 LDA > 2.6 < 3.2 Remission < 2.6 | 27 7 (25.9) 7 (25.9) 5 (18.5) 8 (29.6) | 21 3 (14.3) 8 (38.1) 7 (33.3) 3 (14.3) | 35 16 (45.7) 11 (31.4) 3 (8.6) 5 (14.3) |
12 Months n% HDA > 5.1 MDA > 3.2 < 5.1 LDA > 2.6 < 3.2 Remission < 2.6 | 21 8 (38.1) 7 (33.3) 2 (9.5) 4 (19) | 15 2 (13.3%) 6 (40%) 2 (13.3%) 5 (33.3%) | 25 7 (28) 9 (36) 5 (20) 4 (16) |